{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":2,"youtube":1,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT04613596","nct_id":"NCT04613596","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04613596. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Cohort 1a: Adagrasib twice daily (BID) in combination with pembrolizumab","label":"Phase 2 Cohort 1a: PD-L1 TPS <1%","type":"EXPERIMENTAL"},{"description":"Cohort 1b: Adagrasib BID monotherapy","label":"Phase 2 Cohort 1b: PD-L1 TPS <1%","type":"EXPERIMENTAL"},{"description":"Cohort 2: Adagrasib BID in combination with pembrolizumab","label":"Phase 2 Cohort 2: PD-L1 TPS ≥1%","type":"EXPERIMENTAL"},{"description":"Adagrasib BID in combination with pembrolizumab","label":"Phase 3 Cohort 3 Investigational Arm","type":"EXPERIMENTAL"},{"description":"Pembrolizumab","label":"Phase 3 Cohort 4 Comparator Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-10-31","type":"ESTIMATED"},"conditions":["Advanced Non-Small Cell Lung Cancer","Metastatic Non-Small Cell Lung Cancer"],"enrollment":{"count":626,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Adagrasib","type":"DRUG"},{"name":"Adagrasib","type":"DRUG"},{"name":"Adagrasib","type":"DRUG"},{"name":"Adagrasib","type":"DRUG"},{"name":"Pembrolizumab","type":"DRUG"}],"last_update":"2026-09-16","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation","overall_status":"RECRUITING","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 2: To evaluate the efficacy of Adagrasib monotherapy and in combination with pembrolizumab administered to patients having advanced/metastatic NSCLC.","timeFrame":"22 months"},{"measure":"Phase 3: To compare efficacy of Adagrasib in combination with pembrolizumab versus pembrolizumab","timeFrame":"36 months"}],"references":[],"start_date":{"date":"2020-12-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","url":"https://clinicaltrials.gov/study/NCT04613596"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04613596"}